Literature DB >> 28105229

Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.

Fuyou Zhao1, Qiong Wu1, Xiusong Dai2, Yumei Li1, Huaiyong Gan3, Ri Wang1, Jie Lv4, Yuqing Chen5.   

Abstract

The aim of the present study was to investigate the effect of programmed cell death 1 (PD-1) on osteosarcoma (OD) stem cells and T cells, and to determine their correlation. OS stem cells were sorted and identified from OS MG63 cells. Flow cytometry was used to detect the PD-1 expression of the OS tumor stem cell membrane surface. The expression of PD-1 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR). MTT was used to detect the effect of PD-1 signals on T-cell proliferation. The results indicated that the cancer cells (cultured in DMEM medium containing 10% fetal bovine serum) exhibited clear proliferation within 1 week of cell culture, which showed their strong proliferation and aggressive ability. The formation of tumor cell spheres was dependent on the support of serum nutrition. The proliferation of MG63 cells in the serum culture medium was significantly higher than the number of OS cell spheres in serum-free suspension culture (P<0.05). Pluripotent stem cells in cancer cell spheres exhibited significantly higher cluster of differentiation 133 expression compared with the MG63 cells. The PD-1 expression levels of the cancer cell spheres was significantly increased compared with the MG63 cells, which is consistent with the results of the RT-PCR. In conclusion, the MG63 cell line possesses the features of OS stem cells. The MG63 cell line can express the certain cancer-associated cell markers. The expression of PD-1 in spheres was also increased significantly compared to the MG63 cells, which can reduce the immune function of patients and may be closely associated with the occurrence and development of tumors.

Entities:  

Keywords:  MG63; PD-1; correlation; osteosarcoma; stem cells

Year:  2016        PMID: 28105229      PMCID: PMC5228571          DOI: 10.3892/ol.2016.5311

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

Review 1.  Recent advances in osteosarcoma.

Authors:  Sander M Botter; Dario Neri; Bruno Fuchs
Journal:  Curr Opin Pharmacol       Date:  2014-03-13       Impact factor: 5.547

2.  Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival.

Authors:  Junna Oba; Takeshi Nakahara; Takeru Abe; Akihito Hagihara; Yoichi Moroi; Masutaka Furue
Journal:  J Am Acad Dermatol       Date:  2014-05       Impact factor: 11.527

3.  Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.

Authors:  Yang Liu; Zhimin He; Dapeng Feng; Guodong Shi; Rui Gao; Xiaodong Wu; Weiguo Song; Wen Yuan
Journal:  DNA Cell Biol       Date:  2011-05-25       Impact factor: 3.311

4.  Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling.

Authors:  Naomi H Philip; Christopher P Dillon; Annelise G Snyder; Patrick Fitzgerald; Meghan A Wynosky-Dolfi; Erin E Zwack; Baofeng Hu; Louise Fitzgerald; Elizabeth A Mauldin; Alan M Copenhaver; Sunny Shin; Lei Wei; Matthew Parker; Jinghui Zhang; Andrew Oberst; Douglas R Green; Igor E Brodsky
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

5.  Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma.

Authors:  Wen Wang; Jian Wang; Haihan Song; Jie Liu; Bao Song; Xuecheng Cao
Journal:  Genet Test Mol Biomarkers       Date:  2011-03-31

6.  Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Otto C Boerman; Winette T A van der Graaf
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

8.  Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing's sarcoma.

Authors:  Shufeng Yang; Chaoyang Wang; Yujia Zhou; Guojing Sun; Dongmei Zhu; Suning Gao
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-20

9.  Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma.

Authors:  Dapeng Feng; Xinghai Yang; Shufeng Li; Tielong Liu; Zhipeng Wu; Yuanlin Song; Jian Wang; Wenwu Gao; Quan Huang; Wending Huang; Wei Zheng; Jianru Xiao
Journal:  Genet Test Mol Biomarkers       Date:  2013-03-12

Review 10.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

View more
  1 in total

1.  In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic.

Authors:  Hung-Yun Lin; Yu-Tang Chin; Ya-Jung Shih; Yi-Ru Chen; Matthew Leinung; Kelly A Keating; Shaker A Mousa; Paul J Davis
Journal:  Oncotarget       Date:  2018-09-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.